19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management

19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management

Chronic pain is no longer viewed merely as acute pain that has persisted past an arbitrary calendar duration; it represents a distinct pathological disease state characterized by maladaptive neuroplastic rewiring, structural synaptic reorganization, and central sensitization. Managing chronic and cancer pain requires a deep understanding of neurochemical signaling pathways, rigorous application of diagnostic criteria, and a structured escalation ladder from targeted pharmacotherapy to advanced neuromodulation and neurolytic interventional procedures.

---

1. Pathophysiology and Classification of Chronic and Neuropathic Pain

Definitions and Chronification Mechanisms

• Chronic Pain: Defined by the International Association for the Study of Pain (IASP) as pain that persists or recurs for $> 3\text{ months}$ beyond the expected biological healing time of normal tissue. This transition from physiological nociception to chronic pathological pain involves phenotypic alterations in primary afferents, sustained loss of inhibitory GABAergic and glycinergic dorsal horn interneurons, microglial and astrocytic neuroinflammation, and maladaptive functional reorganization of the primary somatosensory cortex.
• Neuropathic Pain: Defined by the IASP as "pain caused by a lesion or disease of the somatosensory nervous system." Unlike nociceptive pain (which arises from actual or threatened damage to non-neural tissue and appropriate activation of nociceptors), neuropathic pain arises from direct damage to peripheral nerves, plexuses, nerve roots, or central tracts:
  • Positive Symptoms: Aberrant sensory gain reflecting neuronal hyperexcitability and spontaneous ectopic firing: spontaneous burning or shooting dysesthesias, hyperalgesia (exaggerated painful response to a normally painful stimulus), and allodynia (pain evoked by an innocuous stimulus such as light cotton touch, warmth, or mild cold).
  • Negative Symptoms: Sensory deficit reflecting axonal loss or conduction block: hypoesthesia (reduced touch sensation), hypalgesia (reduced pinprick sensation), and loss of vibration, thermal, and proprioceptive modalities.

---

2. Common Clinical Neuropathic Pain Syndromes

Post-Herpetic Neuralgia (PHN)

• Etiology & Definition: Severe neuropathic pain persisting for $\ge 3\text{ months}$ following the crusted resolution of an acute Herpes Zoster (shingles) vesicular rash.
• Pathophysiology: Reactivation of latent Varicella-Zoster Virus (VZV) residing in the dorsal root ganglion (DRG) or trigeminal ganglion. The viral cascade produces acute hemorrhagic ganglionitis, chronic neuronal necrosis, peripheral axonal deafferentation, and loss of inhibitory interneurons in the dorsal horn. Surviving primary afferents express abnormal densities of voltage-gated sodium channels, firing spontaneously.
• Clinical Presentation: Unilateral, dermatomal distribution (most commonly thoracic $T3 - T12$, or ophthalmic trigeminal $V_1$). Patients report excruciating continuous burning or aching pain, punctuated by lancinating electric shock-like paroxysms, accompanied by profound tactile allodynia (inability to tolerate shirts or bedsheets touching the skin). Preventable via recombinant zoster vaccination (Shingrix).

Diabetic Peripheral Neuropathy (DPN)

• Etiology: Symmetrical distal sensorimotor polyneuropathy resulting from chronic hyperglycemia, accumulation of advanced glycation end-products (AGEs), sorbitol accumulation via the aldose reductase polyol pathway, microvascular endoneurial ischemia ("vasa nervorum" arteriolosclerosis), and free radical oxidative stress.
• Clinical Presentation: Classic "stocking-and-glove" distribution, beginning insidiously in the toes and feet before ascending symmetrically up the lower legs and hands. Characterized by nocturnal burning pain, numbness, hyperalgesia, loss of Achilles tendon reflexes, and loss of protective vibratory and monofilament sensation, predisposing to neuropathic foot ulceration and Charcot neuroarthropathy.

Trigeminal Neuralgia (Tic Douloureux)

• Etiology & Anatomy: Unilateral, excruciating, paroxysmal facial pain strictly confined to one or more divisions of the fifth cranial nerve (trigeminal nerve), most commonly the maxillary ($V_2$) and mandibular ($V_3$) divisions ($V_1$ ophthalmic involvement occurs in $< 5\%$ of cases).
• Pathophysiology: In $> 80 - 90\%$ of classic cases, the underlying etiology is mechanical neurovascular compression of the trigeminal nerve root entry zone (REZ) in the prepontine cistern by an aberrant, ectatic arterial loop—most frequently the Superior Cerebellar Artery (SCA), or less commonly the anterior inferior cerebellar artery (AICA) or petrosal vein. Pulsatile arterial compression induces focal deafferentation and demyelination, causing pathological ephaptic cross-talk ("electrical short-circuiting") between non-nociceptive $A\beta$ tactile fibers and nociceptive $A\delta$/C fibers.
• Clinical Features: Paroxysms of searing, lancinating, electric shock-like stabbing pain lasting from a fraction of a second up to 2 minutes, separated by refractory pain-free intervals. Paroxysms are triggered by innocuous, non-painful mechanical stimulation of localized "trigger zones" on the face or oral cavity: light touch, chewing, talking, smiling, shaving, washing the face, brushing teeth, or even a light breeze.
• Medical Therapy (First-Line): Carbamazepine ($200 - 1200\text{ mg/day}$) or oxcarbazepine ($600 - 1800\text{ mg/day}$). These agents block voltage-gated sodium channels in their inactivated state, halting high-frequency neuronal discharges. Adverse Effects of Carbamazepine: Sedation, dizziness, ataxia, hyponatremia (SIADH), drug-induced agranulocytosis, aplastic anemia, and severe cutaneous reactions (toxic epidermal necrolysis and Stevens-Johnson syndrome, strongly correlated with the HLA-B*1502 allele in patients of Asian descent).
• Surgical & Interventional Therapy:
  • Microvascular Decompression (MVD / Jannetta Procedure): The definitive surgical treatment of choice for medically refractory trigeminal neuralgia. A suboccipital retrosigmoid craniotomy is performed to mobilize the compressing superior cerebellar artery away from the trigeminal root entry zone, placing a permanent inert Teflon felt sponge between the vessel and the nerve. High initial cure rate ($> 85 - 90\%$) with preservation of facial sensation.
  • Percutaneous Rhizotomy / Radiosurgery: Percutaneous balloon compression, glycerol rhizotomy, radiofrequency thermocoagulation via the foramen ovale, or stereotactic Gamma Knife radiosurgery.

Phantom Limb Pain vs. Stump Pain

• Phantom Limb Pain: Painful sensations localized to the missing, amputated body part (cramping, burning, twisting, or electric shock sensations). Driven by peripheral ectopic firing from stump neuromas combined with profound cortical somatosensory reorganization (the cortical homunculus representation of adjacent body regions, such as the face or trunk, invades and expands into the deafferented amputation territory).
• Phantom Limb Sensation: Non-painful perception that the missing limb is still intact, retaining sensation, volume, or warmth (experienced by $> 80\%$ of amputees; benign).
• Stump (Residual Limb) Pain: Pain localized directly to the physical margin of the surgical stump, typically driven by local mechanical socket friction, surgical scar ischemia, underlying heterotopic ossification/bone spur, or localized neuroma formation (focal nerve bulb tender to direct palpation, reproducing radiating dysesthesias; positive Tinel's sign).

---

3. Pharmacological Treatment Ladder for Neuropathic Pain

+---------------------------------------------------------------------------------------------------------+
|                               NEUROPATHIC PAIN PHARMACOTHERAPY LADDER                                   |
|                                                                                                         |
|  Line of Therapy   Drug Class & Agents            Mechanism of Action      Major Toxicities & Traps     |
|  ----------------  -----------------------------  -----------------------  ---------------------------  |
|  FIRST-LINE        Gabapentinoids:                Binds alpha-2-delta-1    Drowsiness, dizziness,       |
|                    - Pregabalin (150-600 mg/d)    subunit of voltage-      peripheral edema, ataxia;    |
|                    - Gabapentin (900-3600 mg/d)   gated Ca2+ channels      dose-reduce in renal disease |
|                                                                                                         |
|  FIRST-LINE        SNRIs:                         Inhibits reuptake of     Nausea, insomnia, sweating,  |
|                    - Duloxetine (60-120 mg/d)     5-HT and NE; enhances    hypertension (venlafaxine);  |
|                    - Venlafaxine (150-225 mg/d)   descending inhibition    withdrawal on abrupt stop    |
|                                                                                                         |
|  FIRST-LINE        TCAs:                          Dual 5-HT/NE reuptake    Anticholinergic: dry mouth,  |
|                    - Amitriptyline (10-75 mg/d)   inhibition; Na+ channel  blurred vision, urinary      |
|                    - Nortriptyline (10-75 mg/d)   and NMDA blockade        retention; fatal cardiotoxic |
|                                                                            arrhythmias in overdose      |
|                                                                                                         |
|  SECOND-LINE       Topical Patches:               Lidocaine: local Na+ blk Skin irritation; Capsaicin   |
|                    - Lidocaine 5% patch           Capsaicin: TRPV1 agonist causes severe initial        |
|                    - Capsaicin 8% patch           -> substance P depletion burning -> desensitization   |
|                                                                                                         |
|  SECOND-LINE       Tramadol (50-400 mg/d)         Weak mu-agonist +        Nausea, seizures; Serotonin  |
|                                                   5-HT/NE reuptake blk     Syndrome with SSRIs/SNRIs    |
|                                                                                                         |
|  THIRD-LINE        Strong Opioids:                Mu-opioid receptor       Opioid-induced hyperalgesia, |
|                    - Morphine, Oxycodone          activation               tolerance, physical          |
|                    - Fentanyl, Buprenorphine                               dependence, constipation     |
+---------------------------------------------------------------------------------------------------------+

First-Line Agents

1. Gabapentinoids (Pregabalin & Gabapentin):
   • Mechanism: Do not bind GABA receptors despite their structural naming. Instead, they bind with high affinity to the auxiliary $\alpha_2\delta-1$ subunit of presynaptic voltage-gated calcium channels ($P/Q\text{ and }N\text{-type}$) in the dorsal horn and neocortex. This inhibits calcium influx upon depolarization, reducing the vesicular exocytotic release of excitatory neurotransmitters (glutamate, substance P, and CGRP).
   • Pharmacokinetics: Eliminated entirely unchanged via renal excretion. Dosing must be adjusted in renal impairment. Pregabalin exhibits rapid, linear, dose-proportional oral bioavailability ($> 90\%$), whereas gabapentin relies on saturable L-amino acid active gut transporters, yielding nonlinear bioavailability that decreases as the dose increases.
2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs: Duloxetine & Venlafaxine):
   • Mechanism: Inhibit presynaptic reuptake transporters for serotonin ($5\text{-HT}$) and norepinephrine (NE), markedly potentiating descending monoaminergic inhibitory pain pathways terminating on dorsal horn neurons.
   • Indications: Highly effective in diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal back pain.
3. Tricyclic Antidepressants (TCAs: Amitriptyline & Nortriptyline):
   • Mechanism: Triad of actions: potent inhibition of both serotonin and norepinephrine reuptake; blockade of voltage-gated sodium channels; and non-competitive blockade of NMDA receptors.
   • Adverse Effects & Safety Traps: Administered at low nocturnal doses ($10 - 75\text{ mg}$ at bedtime). Major limiting adverse effects include anticholinergic symptoms (dry mouth, blurred vision, severe constipation, urinary retention), antihistaminergic sedation, and $\alpha_1$-adrenergic antagonism (orthostatic hypotension). Cardiotoxicity: Possess quinidine-like Class IA antiarrhythmic actions, prolonging PR, QRS, and QTc intervals; strictly contraindicated in patients with severe ischemic heart disease, bundle branch block, or cardiac conduction delays. Highly lethal in overdose due to intractable refractory ventricular arrhythmias.

Second-Line and Topical Agents

• Topical Lidocaine $5\%$ Patch: Applied directly over intact skin (12 hours on, 12 hours off); penetrates epidermis to block overexpressed sodium channels in cutaneal nerve fibers with negligible systemic absorption. First-line for localized peripheral neuropathies like post-herpetic neuralgia in frail elderly patients.
• Topical Capsaicin $8\%$ Patch: High-concentration synthetic TRPV1 agonist. Initial application activates primary nociceptive nerve terminals, triggering intense burning pain. Prolonged massive calcium influx induces mitochondrial swelling, functional desensitization, and reversible degeneration/retraction of epidermal nociceptive nerve fibers, depleting substance P. A single 60-minute in-clinic application provides up to 3 months of sustained pain relief.
• Tramadol: Centrally acting dual-mechanism synthetic analgesic: weak $\mu$-opioid receptor agonist combined with central serotonin and norepinephrine reuptake inhibition. Warning: Lowers seizure threshold and carries a significant risk of precipitating Serotonin Syndrome when combined with SSRIs, SNRIs, or MAOIs.

---

4. Complex Regional Pain Syndrome (CRPS)

Complex Regional Pain Syndrome is an incapacitating, chronic neuropathic pain condition that typically affects an extremity following trauma, characterized by autonomic, inflammatory, and motor disturbances.

Classification: Type I vs. Type II

• CRPS Type I (formerly Reflex Sympathetic Dystrophy - RSD): Develops following an initiating noxious event (e.g., distal radius Colles fracture, sprain, crush injury, or surgery) WITHOUT any identifiable, demonstrable lesion of a major peripheral nerve ($> 90\%$ of clinical cases).
• CRPS Type II (formerly Causalgia): Develops following a documented, demonstrable structural injury to a major peripheral nerve (e.g., complete or partial transection of the median, sciatic, or tibial nerve).

The Budapest Diagnostic Criteria

Diagnosis of CRPS requires: (1) Continuing pain disproportionate in time or degree to any known inciting event; (2) Patient reports at least 1 symptom in at least 3 of the 4 categories; (3) Clinician documents at physical examination at least 1 sign in at least 2 of the 4 categories:

Multimodal Treatment Strategies

• Physical & Occupational Therapy: The absolute cornerstone of management. Active functional mobilization, graded motor imagery, mirror visual feedback therapy, and desensitization programs must be initiated immediately to prevent fixed dystonic contractures and cortical neglect.
• Pharmacological Interventions: Vitamin C ($500\text{ mg/day}$ for 50 days) after wrist fracture reduced CRPS in early trials, but later evidence is conflicting and guidelines differ; bisphosphonates (intravenous neridronate or pamidronate, or high-dose oral alendronate) inhibit osteoclast activity and showed benefit in small trials of early CRPS ($< 6\text{ months}$); gabapentinoids; short courses of oral corticosteroids during acute warm inflammatory stages.
• Sympathetic Nerve Blocks:
  • Stellate Ganglion Block (Cervicothoracic Sympathetic Block): Usually performed at C6 (Chassaignac's tubercle) or C7; the stellate ganglion itself lies at C7-T1, anterior to the C7 transverse process and the neck of the first rib, and the injectate spreads caudally to reach it. Confirmed successful block produces an ipsilateral Horner's syndrome (ptosis, miosis, anhidrosis, enophthalmos, conjunctival injection) and a temperature rise of $> 1.5 - 2.0^\circ\text{C}$ in the affected upper extremity. Used for upper limb CRPS.
  • Lumbar Sympathetic Block: Targets the sympathetic chain at the anterolateral border of the L2, L3, and L4 vertebral bodies for lower extremity CRPS.

---

5. Cancer Pain Management and Interventional Therapies

The WHO Analgesic Ladder

Originally established in 1986, the World Health Organization ladder provides a validated stepwise escalation approach for cancer pain:

• Step 1: Mild Pain (VAS 1 - 3): Non-opioid analgesics (paracetamol, NSAIDs) $\pm$ adjuvant medications (gabapentinoids, antidepressants, corticosteroids).
• Step 2: Moderate Pain (VAS 4 - 6): "Weak" opioids (codeine, tramadol, dihydrocodeine) $\pm$ Step 1 non-opioids $\pm$ adjuvants. Note: Modern oncology guidelines frequently skip Step 2, moving directly to low-dose strong opioids.
• Step 3: Severe Pain (VAS 7 - 10): Strong opioids (morphine, oxycodone, hydromorphone, fentanyl, methadone, buprenorphine) $\pm$ Step 1 non-opioids $\pm$ adjuvants.
• Step 4 (Interventional Step, an informal addition not part of the original WHO ladder): Minimally invasive interventional techniques for refractory, intolerable pain: neurolytic blocks, spinal cord stimulation, and intrathecal drug delivery systems.

Breakthrough Cancer Pain (BTcP) and Opioid Rotation

• Breakthrough Pain Dosing: Breakthrough pain is a transient exacerbation of severe pain that occurs over a baseline of otherwise well-controlled background pain. Breakthrough rescue doses should be formulated using rapid-onset immediate-release opioids calculated at $10 - 16.7\%$ ($1/6\text{th}$) of the total 24-hour baseline Oral Morphine Equivalent (OME) dose, administered every $1 - 2\text{ hours}$ as needed.
• Equianalgesic Ratios and Incomplete Cross-Tolerance:
  • Oral Morphine to Oral Oxycodone: Ratio is approximately $1.5 : 1$ ($15\text{ mg}$ oral morphine $\approx 10\text{ mg}$ oral oxycodone).
  • Oral Morphine to IV/Subcutaneous Morphine: Ratio is $3 : 1$ ($30\text{ mg}$ oral morphine $\approx 10\text{ mg}$ IV/SC morphine due to extensive first-pass hepatic glucuronidation).
  • Transdermal Fentanyl: $25\text{ }\mu\text{g/h}$ transdermal patch $\approx 60\text{ mg/24h}$ of oral morphine equivalent.
  • Rule of Incomplete Cross-Tolerance: When switching from one strong opioid to another, calculate the equianalgesic equivalent dose and then decrease the calculated dose by $25 - 50\%$ to avoid fatal accidental overdose, because the patient is not fully tolerant to the new drug's specific receptor affinity profile!

Interventional Pain Therapies

+---------------------------------------------------------------------------------------------------------+
|                                ADVANCED INTERVENTIONAL PAIN THERAPIES                                   |
|                                                                                                         |
|  Intervention        Anatomical Target       Mechanism & Technique          Primary Indication & Risks  |
|  ------------------  ----------------------  -----------------------------  --------------------------  |
|  Celiac Plexus       Retrocrural /           Chemical neurolysis with       Intractable pain from       |
|  Neurolysis          transcrural at T12-L1   50-100% dehydrated alcohol     pancreatic cancer; causes   |
|                      anterior to aorta       or 6-10% phenol                hypotension, diarrhea,      |
|                                                                             Adamkiewicz paraplegia risk |
|                                                                                                         |
|  Superior            Retroperitoneal at      Chemical neurolysis of pelvic  Pelvic cancer visceral      |
|  Hypogastric Block   L5-S1 interspace        visceral afferents             pain (cervix, bladder, rec) |
|                                                                                                         |
|  Spinal Cord         Epidural space over     Gate Control Theory: A-beta    Failed Back Surgery         |
|  Stimulation (SCS)   dorsal columns (T8-T10) dorsal column stimulation      Syndrome (FBSS), CRPS;      |
|                                              releases GABA/glycine in horn  suppresses neuropathic pain |
|                                                                                                         |
|  Intrathecal Drug    Subarachnoid space via  Direct CSF delivery: Morphine, Refractory cancer pain;     |
|  Delivery (IDDS)     programmable pump       Ziconotide (N-type Ca2+ blk),  doses 1/100-1/300th oral;   |
|                                              Baclofen (GABA-B agonist)      Ziconotide has no tolerance |
+---------------------------------------------------------------------------------------------------------+

1. Celiac Plexus Neurolysis:
   • Anatomy & Indications: The celiac plexus surrounds the anterolateral aspect of the abdominal aorta and celiac trunk at T12 - L1, deep to the crura of the diaphragm. Indicated for severe visceral pain from malignancies of the upper abdomen (pancreatic adenocarcinoma, gastric cancer, gallbladder cancer).
   • Neurolytic Technique: Performed under fluoroscopic or CT guidance using $50 - 100\%$ dehydrated alcohol (causes extraction of membrane cholesterol and cellular dehydration) or $6 - 10\%$ phenol (causes protein denaturation and non-selective coagulation necrosis).
   • Adverse Effects & Risks: Sympathetic denervation produces unopposed parasympathetic tone: transient orthostatic hypotension ($30 - 50\%$, due to splanchnic pooling) and transient diarrhea ($60 - 70\%$). Catastrophic Hazard: Inadvertent injury, spasm, or intra-arterial injection into the Great Radicular Artery of Adamkiewicz (arteria radicularis magna, arising between T9 and L2) produces anterior spinal artery thrombosis and permanent anterior spinal cord ischemic necrosis resulting in permanent flaccid paraplegia.
2. Superior Hypogastric Plexus Block:
   • Located retroperitoneally anterior to the lower third of the L5 vertebral body and sacral promontory (L5 - S1). Indicated for intractable pelvic visceral cancer pain (cervical, prostate, bladder, or rectal malignancies).
3. Spinal Cord Stimulation (SCS):
   • Mechanism: Based on the Gate Control Theory of Pain (Melzack & Wall, 1965). Electrical stimulation of large, heavily myelinated, low-threshold $A\beta$ sensory fibers in the dorsal columns induces antidromic and orthodromic action potentials that activate inhibitory interneurons in the substantia gelatinosa (Lamina II), releasing GABA and glycine to suppress ascending nociceptive transmission from $A\delta$ and C fibers.
   • Indications: Failed Back Surgery Syndrome (FBSS / Persistent Spinal Pain Syndrome), medically refractory CRPS Type I and II, and ischemic pain from inoperable peripheral vascular disease or refractory angina.
4. Intrathecal Drug Delivery Systems (IDDS / Pain Pumps):
   • Subcutaneously implanted programmable pump delivering medications directly into the subarachnoid space adjacent to dorsal horn receptors. Achieves equianalgesic pain relief using $1/100\text{th} - 1/300\text{th}$ of the oral morphine dose, minimizing systemic side effects.
   • Agents: Morphine, hydromorphone, and Ziconotide (synthetic peptide derived from the cone snail Conus magus, which selectively and reversibly blocks N-type voltage-gated calcium channels on primary afferents; produces zero opioid tolerance or physical dependence, but can cause neuropsychiatric adverse effects including hallucinations and psychosis).